Myriad Genetics (MYGN) Interest Expenses (2009 - 2026)

Myriad Genetics has disclosed Interest Expenses across 17 years of filings, most recently posting $4.1 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 412.5% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $13.8 million (up 345.16% YoY), while the FY2025 annual figure was $10.5 million, up 275.0% from the prior year.
• Interest Expenses slipped to $4.1 million in Q1 2026, from $4.4 million in the prior quarter.
• Over the last five years, Interest Expenses for MYGN reached as high as $4.4 million in Q4 2025 and fell as low as $500000.0 in Q1 2023.
• The 5-year median for Interest Expenses is $800000.0 (2022), against an average of $1.4 million.
• Annual changes were most pronounced in 2022 — Interest Expenses slumped 70.0% — and 2025, when it jumped 528.57%.
• A 5-year view of Interest Expenses shows it stood at $900000.0 in 2022, then changed by 0.0% to $900000.0 in 2023, then retreated by 22.22% to $700000.0 in 2024, then jumped by 528.57% to $4.4 million in 2025, then dropped by 6.82% to $4.1 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $4.1 million, $4.4 million, and $3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.